197 related articles for article (PubMed ID: 36544210)
1. Cost-effectiveness analysis of molecular testing for cytologically indeterminate thyroid nodules.
Dharampal N; Smith K; Harvey A; Paschke R; Rudmik L; Chandarana S
J Otolaryngol Head Neck Surg; 2022 Dec; 51(1):46. PubMed ID: 36544210
[TBL] [Abstract][Full Text] [Related]
2. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
[No Abstract] [Full Text] [Related]
3. Molecular Testing for Thyroid Nodules of Indeterminate Cytology: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2022; 22(2):1-111. PubMed ID: 35591972
[TBL] [Abstract][Full Text] [Related]
4. The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology.
Duick DS; Klopper JP; Diggans JC; Friedman L; Kennedy GC; Lanman RB; McIver B
Thyroid; 2012 Oct; 22(10):996-1001. PubMed ID: 22873825
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules.
Li H; Robinson KA; Anton B; Saldanha IJ; Ladenson PW
J Clin Endocrinol Metab; 2011 Nov; 96(11):E1719-26. PubMed ID: 21865367
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of reflexive versus selective molecular testing for indeterminate thyroid nodules.
Hu QL; Schumm MA; Zanocco KA; Yeh MW; Livhits MJ; Wu JX
Surgery; 2022 Jan; 171(1):147-154. PubMed ID: 34284895
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial.
Livhits MJ; Zhu CY; Kuo EJ; Nguyen DT; Kim J; Tseng CH; Leung AM; Rao J; Levin M; Douek ML; Beckett KR; Cheung DS; Gofnung YA; Smooke-Praw S; Yeh MW
JAMA Oncol; 2021 Jan; 7(1):70-77. PubMed ID: 33300952
[TBL] [Abstract][Full Text] [Related]
8. Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy.
Sacks WL; Bose S; Zumsteg ZS; Wong R; Shiao SL; Braunstein GD; Ho AS
Cancer Cytopathol; 2016 Oct; 124(10):722-728. PubMed ID: 27347838
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of lobectomy versus genetic testing (Afirma®) for indeterminate thyroid nodules: Considering the costs of surveillance.
Balentine CJ; Vanness DJ; Schneider DF
Surgery; 2018 Jan; 163(1):88-96. PubMed ID: 29128178
[TBL] [Abstract][Full Text] [Related]
10. National differences in cost analysis of Afirma Genomic sequencing classifier.
Ronen O; Oichman M
Clin Endocrinol (Oxf); 2021 Apr; 94(4):717-724. PubMed ID: 33349964
[TBL] [Abstract][Full Text] [Related]
11. Relationship Between Sonographic Characteristics and Afirma Gene Expression Classifier Results in Thyroid Nodules With Indeterminate Fine-Needle Aspiration Cytopathology.
Zhu QL; Faquin WC; Samir AE
AJR Am J Roentgenol; 2015 Oct; 205(4):861-5. PubMed ID: 26397337
[TBL] [Abstract][Full Text] [Related]
12. Testing for Afirma in Thyroid Nodules with High-Risk Indeterminate Cytology (TIR3B): First Italian Experience.
Andrioli M; Carocci S; Alessandrini S; Amini M; Van Doorne D; Pace D; Lauria A; Raffaelli M; Trimboli P
Endocr Pathol; 2020 Mar; 31(1):46-51. PubMed ID: 31960284
[TBL] [Abstract][Full Text] [Related]
13. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience.
Lastra RR; Pramick MR; Crammer CJ; LiVolsi VA; Baloch ZW
Cancer Cytopathol; 2014 Oct; 122(10):737-44. PubMed ID: 25123499
[TBL] [Abstract][Full Text] [Related]
14. Selective use of Molecular Testing Based on Sonographic Features of Cytologically Indeterminate Thyroid Nodules: A Decision Analysis.
Zanocco KA; Wang MM; Yeh MW; Livhits MJ
World J Surg; 2020 Feb; 44(2):393-401. PubMed ID: 31538250
[TBL] [Abstract][Full Text] [Related]
15. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
Gortakowski M; Feghali K; Osakwe I
Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
[No Abstract] [Full Text] [Related]
16. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.
McIver B; Castro MR; Morris JC; Bernet V; Smallridge R; Henry M; Kosok L; Reddi H
J Clin Endocrinol Metab; 2014 Nov; 99(11):4069-77. PubMed ID: 24780044
[TBL] [Abstract][Full Text] [Related]
17. Performance of Afirma Gene Sequencing Classifier versus Gene Expression Classifier in thyroid nodules with indeterminate cytology.
Yang Z; Zhang T; Layfield L; Esebua M
J Am Soc Cytopathol; 2022; 11(2):74-78. PubMed ID: 34366280
[TBL] [Abstract][Full Text] [Related]
18. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
19. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.
Brauner E; Holmes BJ; Krane JF; Nishino M; Zurakowski D; Hennessey JV; Faquin WC; Parangi S
Thyroid; 2015 Jul; 25(7):789-96. PubMed ID: 25962906
[TBL] [Abstract][Full Text] [Related]
20. Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.
Silaghi CA; Lozovanu V; Georgescu CE; Georgescu RD; Susman S; Năsui BA; Dobrean A; Silaghi H
Front Endocrinol (Lausanne); 2021; 12():649522. PubMed ID: 34054725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]